Xencor Inc's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 3.99, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the second quarter 2026. Average receivable collection period, for the Xencor Inc in Jun 30 2026 quarter, has decreased to 91 days, compared to 104 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 458 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 2985 to 3152.

What is Receivable Turnover Ratio?
What is Xencor Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

XNCR Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	-11.19 %	-68.24 %	-51.85 %	-15.72 %	32.38 %
Y / Y Revenue Change	17.46 %	-86.2 %	-46.51 %	18 %	82.41 %
Receivable Turnover Ratio (TTM)	3.99	3.52	3.68	3.57	3.42
XNCR's Total Ranking	# 3152	# 2985	# 2701	# 2812	# 2705
Accounts Receivable average collection period days	92	104	99	102	107
Seq. Receivable Change	251.92 %	-59.04 %	34.37 %	-54.15 %	25.85 %
Seq. Revenue Change	1034.21 %	-84.01 %	34.47 %	-51.85 %	33.23 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 150
Healthcare Sector	# 459
Overall Market	# 3152

Receivable Turnover Ratio Statistics
High	Average	Low
0.42	0.19	0.07
(Mar 31 2022)		(Jun 30 2015)

XNCR Company Profile • Back to XNCR Efficiency Comparisons • Compare XNCR Receivables Turnover Ratio to its Competitors

Financial Statements
Xencor Inc's Accounts Receivable	$ 42 Millions	Visit XNCR's Balance sheet
Xencor Inc's Sales TTM	$ 105 Millions	Visit XNCR's Income Statement
Sources of XNCR's Revenues		Visit XNCR's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
XNCR's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
XNCR's Growth Rates	XNCR's Roa	XNCR's Inventory Turnover Ratio	XNCR's Dividend Comparisons
XNCR's Profitability Ratios	XNCR's Roi	XNCR's Asset Turnover Ratio	XNCR's Dividend Growth
XNCR's Valuation Ratios	XNCR's Roe	XNCR's Financial Strength Ratios	XNCR's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Nephros Inc	6.83	$ 21.686 Millions	$ 3.173 Millions
Medpace Holdings Inc	6.82	$ 2,782.288 Millions	$ 408.189 Millions
Opko Health Inc	6.79	$ 587.896 Millions	$ 86.589 Millions
Atara Biotherapeutics Inc	6.79	$ 6.452 Millions	$ 0.950 Millions
Rapid Micro Biosystems Inc	6.76	$ 34.545 Millions	$ 5.111 Millions
Universal Health Services Inc	6.75	$ 18,114.487 Millions	$ 2,683.492 Millions
Delcath Systems Inc	6.73	$ 94.058 Millions	$ 13.981 Millions
3m Company	6.72	$ 25,180.000 Millions	$ 3,747.750 Millions
Phibro Animal Health Corporation	6.70	$ 1,516.861 Millions	$ 226.555 Millions
Envista Holdings Corporation	6.69	$ 2,856.400 Millions	$ 427.250 Millions
Solventum Corporation	6.69	$ 8,310.000 Millions	$ 1,243.000 Millions
Eton Pharmaceuticals Inc	6.67	$ 105.279 Millions	$ 15.783 Millions
Neuropace Inc	6.65	$ 98.620 Millions	$ 14.834 Millions
Aspira Women s Health inc	6.65	$ 9.029 Millions	$ 1.358 Millions
Bionano Genomics Inc	6.62	$ 30.176 Millions	$ 4.556 Millions
Livanova Plc	6.62	$ 1,470.112 Millions	$ 222.035 Millions
Agilon Health Inc	6.61	$ 5,920.015 Millions	$ 895.120 Millions
Liquidia Corporation	6.61	$ 450.907 Millions	$ 68.198 Millions
Beone Medicines Ltd	6.58	$ 6,128.238 Millions	$ 930.639 Millions
Editas Medicine Inc	6.57	$ 47.005 Millions	$ 7.156 Millions
Pmgc Holdings Inc	6.57	$ 2.579 Millions	$ 0.393 Millions
Embecta Corp	6.50	$ 1,019.700 Millions	$ 156.775 Millions
Moderna Inc	6.49	$ 2,228.000 Millions	$ 343.250 Millions
Intellia Therapeutics Inc	6.44	$ 59.506 Millions	$ 9.243 Millions
Cvrx inc	6.44	$ 60.164 Millions	$ 9.345 Millions
Tarsus Pharmaceuticals Inc	6.43	$ 606.331 Millions	$ 94.240 Millions
Schrodinger Inc	6.43	$ 259.035 Millions	$ 40.267 Millions
Verastem Inc	6.42	$ 87.526 Millions	$ 13.640 Millions
Haemonetics Corporation	6.42	$ 1,351.722 Millions	$ 210.662 Millions
Ufp Technologies Inc	6.40	$ 632.042 Millions	$ 98.785 Millions

Date modified: 2026-09-10T01:30:03+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.